ArticleThe Journal of pharmacology and experimental therapeutics2019
The 5-HT
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of pharmacology and experimental therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial.Drug and alcohol dependence · 2021Trial
- Lorcaserin modulation of semantic drug cue-elicited effective brain connectivity in persons with cocaine and opioid use disorders.Psychiatry research. Neuroimaging · 2025Article
- The psychedelic (-)-2,5-dimethoxy-4-iodoamphetamine [(-)-DOI] demonstrates efficacy in reducing cocaine reward and motivation in male rats.Psychopharmacology · 2025Article
- Involvement of a stress-responsive orbito-striatal projection in impulsive action in male rats.The international journal of neuropsychopharmacology · 2025Article
- Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats.Molecular psychiatry · 2025Article
- The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.Expert opinion on pharmacotherapy · 2025Review
- Biological sex modulates the efficacy of 2,5-dimethoxy-4-iodoamphetamine (DOI) to mitigate fentanyl demand.Drug and alcohol dependence · 2024Article
- Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats.bioRxiv : the preprint server for biology · 2024Article
- The role of brain serotonin signaling in excessive alcohol consumption and withdrawal: A call for more research in females.Neurobiology of stress · 2024Article
- Genetic polymorphism in HTR2A rs6313 is associated with internet addiction disorder.Frontiers in psychiatry · 2024Article
- Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder.Journal of medicinal chemistry · 2023Article
- Evaluation of the 5-HTPharmacological reports : PR · 2023Article
- Ghrelin receptor antagonist JMV2959 blunts cocaine and oxycodone drug-seeking, but not self-administration, in male rats.Frontiers in pharmacology · 2023Article
- Role of neuropeptide neuromedin U in the nucleus accumbens shell in cocaine self-administration in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- A serotonergic biobehavioral signature differentiates cocaine use disorder participants administered mirtazapine.Translational psychiatry · 2022Article
- Interactions between impulsivity and MDPV self-administration in rats.Addiction biology · 2022Article
- Heightened cocaine-seeking in male rats associates with a distinct transcriptomic profile in the medial prefrontal cortex.Frontiers in pharmacology · 2022Article
- Blockade of 5-Hydroxytryptamine 2A Receptor Attenuates Precipitation of Naloxone-Induced Withdrawal Symptoms in Opioid-Exposed Mice.Frontiers in behavioral neuroscience · 2021Article
- Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration.Neuropharmacology · 2020Article
- Methylation Patterns of theFrontiers in psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Dennis J ShollerCenter for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (D.J.S., S.J.S., R.G.F., N.C.A., K.A.C.); Department of Statistical Sciences and Operations Research, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (E.L.B., Q.W.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Bethesda, Maryland (K.C.R.); and Department of Psychiatry, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (F.G.M.).
Sonja J StutzCenter for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (D.J.S., S.J.S., R.G.F., N.C.A., K.A.C.); Department of Statistical Sciences and Operations Research, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (E.L.B., Q.W.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Bethesda, Maryland (K.C.R.); and Department of Psychiatry, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (F.G.M.).
Robert G FoxCenter for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (D.J.S., S.J.S., R.G.F., N.C.A., K.A.C.); Department of Statistical Sciences and Operations Research, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (E.L.B., Q.W.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Bethesda, Maryland (K.C.R.); and Department of Psychiatry, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (F.G.M.).
Edward L BooneCenter for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (D.J.S., S.J.S., R.G.F., N.C.A., K.A.C.); Department of Statistical Sciences and Operations Research, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (E.L.B., Q.W.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Bethesda, Maryland (K.C.R.); and Department of Psychiatry, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (F.G.M.).
Qin WangCenter for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (D.J.S., S.J.S., R.G.F., N.C.A., K.A.C.); Department of Statistical Sciences and Operations Research, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (E.L.B., Q.W.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Bethesda, Maryland (K.C.R.); and Department of Psychiatry, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (F.G.M.).
Kenner C RiceCenter for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (D.J.S., S.J.S., R.G.F., N.C.A., K.A.C.); Department of Statistical Sciences and Operations Research, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (E.L.B., Q.W.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Bethesda, Maryland (K.C.R.); and Department of Psychiatry, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (F.G.M.).
F Gerard MoellerCenter for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (D.J.S., S.J.S., R.G.F., N.C.A., K.A.C.); Department of Statistical Sciences and Operations Research, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (E.L.B., Q.W.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Bethesda, Maryland (K.C.R.); and Department of Psychiatry, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (F.G.M.).
Noelle C AnastasioCenter for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (D.J.S., S.J.S., R.G.F., N.C.A., K.A.C.); Department of Statistical Sciences and Operations Research, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (E.L.B., Q.W.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Bethesda, Maryland (K.C.R.); and Department of Psychiatry, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (F.G.M.).
Kathryn A CunninghamCenter for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (D.J.S., S.J.S., R.G.F., N.C.A., K.A.C.); Department of Statistical Sciences and Operations Research, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (E.L.B., Q.W.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Bethesda, Maryland (K.C.R.); and Department of Psychiatry, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (F.G.M.) kcunning@utmb.edu.
The University of Texas Medical Branch at Galveston · USNational Institute on Drug Abuse · USVirginia Commonwealth University · US
Funding
Preclinical Assessment of Compounds for Cocaine Use Disorder (CocUD)U54DA038999 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2014 to 2018
$6.8MTranslational Addiction Sciences CenterP50DA033935 · NIDA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CUNNINGHAM, KATHRYN A. · 2013 to 2017
$6.7MTranslational Explorations in Substance Use DisordersT32DA007287 · NIDA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI Kathryn A. Cunningham, Jonathan Dean Hommel · 1994 to 2026
$4.7MNIDA NIH HHS P50 DA033935NIDA NIH HHS T32 DA007287NIDA NIH HHS U54 DA038999
Abstract
Impulsivity and the attentional orienting response to cocaine-associated cues (
Indexed as
CuesAnimalsCocaineDopamine Uptake InhibitorsDose-Response Relationship, DrugFluorobenzenesImpulsive BehaviorMalePiperidinesRatsRats, Sprague-DawleyReaction TimeReceptor, Serotonin, 5-HT2ASelf AdministrationSerotonin AntagonistsUreaCocaineDopamine Uptake InhibitorsFluorobenzenespimavanserinPiperidinesReceptor, Serotonin, 5-HT2ASerotonin AntagonistsUreavolinanserin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.